Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;1(2):66-85.
doi: 10.4161/bact.1.2.15845.

Phage treatment of human infections

Affiliations

Phage treatment of human infections

Stephen T Abedon et al. Bacteriophage. 2011 Mar.

Abstract

Phages as bactericidal agents have been employed for 90 years as a means of treating bacterial infections in humans as well as other species, a process known as phage therapy. In this review we explore both the early historical and more modern use of phages to treat human infections. We discuss in particular the little-reviewed French early work, along with the Polish, US, Georgian and Russian historical experiences. We also cover other, more modern examples of phage therapy of humans as differentiated in terms of disease. In addition, we provide discussions of phage safety, other aspects of phage therapy pharmacology, and the idea of phage use as probiotics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
This figure, based on the data in the 1943 mouse studies of Rene Dubos, provides significant insight into why phage therapy works well even in treating infections that antibiotics can't reach. When he injected the mice intraperitoneally with 109 phages, they quickly appeared in the blood stream, entering the brain, but they were rapidly cleared. However, if the mice were also injected intracerebrally with Shigella dysenteriae, the host for these phages, then 46/64 of the mice survived (as compared with 3/84 in the absence of appropriate viable phage) and the brain level of phage climbed to over 109 per gram. Once the bacteria were cleared, phage levels dropped below detection limits.

References

    1. Kutter E, White T, Kashlev M, Uzan M, McKinney J, Guttman B. Effects on host genome structure and expression. In: Karam JD, editor. Molecular Biology of Bacteriophage T4. Washington, DC: ASM Press; 1994. pp. 357–368.
    1. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1:111–114. doi: 10.4161/bact.1.2.14590. - DOI - PMC - PubMed
    1. Sulakvelidze A, Kutter E. Bacteriophage therapy in humans. In: Kutter E, Sulakvelidze A, editors. Bacteriophages: Biology and Application. Boca Raton, FL: CRC Press; 2005. pp. 381–436.
    1. Sulakvelidze A, Barrow P. Phage therapy in animals and agribusiness. In: Kutter E, Sulakvelidze A, editors. Bacteriophages: Biology and Application. Boca Raton, FL: CRC Press; 2005. pp. 335–380.
    1. Brüssow H. Phage therapy: the western perspective. In: Mc Grath S, van Sinderen D, editors. Bacteriophage: Genetics and Microbiology. Norfolk, UK: Caister Academic Press; 2007. pp. 159–192.

LinkOut - more resources